Investing.com - Ascendis Pharma (NASDAQ:ASND) AS reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Ascendis Pharma AS announced earnings per share of €-2.21 on revenue of €6.83M. Analysts polled by Investing.com anticipated EPS of €-2.05 on revenue of €4.55M.
Ascendis Pharma AS shares are down 41.96% from the beginning of the year, still down 56.31% from its 52 week high of €178.71 set on September 3, 2021. They are under-performing the Nasdaq which is down 27.36% from the start of the year.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings beat by J&J on April 19, who reported EPS of €2.67 on revenue of €23.43B, compared to forecasts EPS of €2.59 on revenue of €23.62B.
UnitedHealth had beat expectations on April 14 with first quarter EPS of €5.49 on revenue of €80.15B, compared to forecast for EPS of €5.36 on revenue of €78.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar